Biomerica, Inc. (BMRA)

Every figure this model derived for BMRA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-02-28.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

The ratios

The figures themselves rather than their scores — what somebody looking up BMRA on one particular measure came for.

Everything else this filing tags

348 more elements from BMRA's own XBRL that this model has no measure for, newest reading each, largest first. Nothing here is converted, added up or renamed — it is the filing's own element names and the filing's own numbers.

What to be careful about

What this model itself distrusts about BMRA's figures. Written by the derivation as it ran, not added afterwards.

• no current capital expenditure tagged (last tagged 2024-05-31); treated as zero, so free cash flow is overstated and equals operating cash flow
• the market value here was 5.6M: 3.1M shares from the filing at the quoted price. The price feed reports 4.6M shares, and that count at this same price gives 8.3M, which is the value the feed itself reports. So the two counts are of different things — a depositary receipt against the ordinary shares behind it, or a count filed in thousands — and the count the price belongs to is used
• there is no operating profit to value; valuation rests on EV/revenue (1.6x) instead
• no debt and no profit, so interest cover cannot be measured; scored on cash runway instead: 1M of net cash against a 3M annual burn is 0.4 years
• analyst estimate not used: trailing EPS is not positive, so a growth rate would be meaningless
• durability rests on 3 of 4 inputs; not tagged: contracted coverage